Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC’s Regulatory Announcement

Abstract:
Neuftec Limited, the proprietor of the original nano-particulate cerium oxide fuel catalyst technology, which recently issued a claim against Oxonica Energy Limited, a wholly owned subsidiary of Oxonica PLC, for infringement of its European Patent in the High Court of Justice, has commented on a fundamental inaccuracy in Oxonica's AGM Statement issued by Dr Matthews (CEO) on 19 June 2008.

Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC’s Regulatory Announcement

Dominica | Posted on June 19th, 2008

Dr Kevin Matthews stated in the recent Regulatory Announcement that:
"In 2007 Neuftec acknowledged that Envirox as supplied by Nyacol, Oxonica's strategic partner, does not fall within the claims of their granted patent, EP(UK) 1299 508."

In May 2007, Oxonica provided Neuftec with a confidential statement containing what it claimed to be the chemical composition of Envirox sold to Petrol Ofisi. Based on that information alone, Neuftec confirmed in June 2007 that the second source product supplied to Petrol Ofisi did not come within the scope of claims of Neuftec's patent. Neuftec has never acknowledged that Envirox products sold to customers other than Petrol Ofisi did not infringe Neuftec's European patent.
Neuftec has obtained samples of Oxonica's Envirox formulation produced by Nyacol and conducted a preliminary analysis of the formulation. The results of this analysis confirm that the Nyacol Envirox formulation does not match the compostion statement issued to Neuftec by Oxonica.

Neuftec Limited thus reserves its position regarding its rights to claim infringement in respect of all other formulations of Envirox supplied to other parties.

As reported earlier this month, the latest alleged infringement occurred when Oxonica shipped Envirox formulations to Italy for use in Italian Government laboratory emission testing. Neuftec is continuing it's investigations with customers, distributors & agents of Oxonica to determine the extent of the alleged infringement. Neuftec issued proceedings to seek an injunction against Oxonica as well as damages in relation to product already sold and delivery up or destruction of all articles that would infringe Neuftec's European patent.

####

About Neuftec Limited
Neuftec is a research & development company that owns patents in the fuel catalyst technology sector used in the production of the first version of EnviroxTM (2001-2007) that was manufactured by Advanced Nanotechnology ("ANO") of Australia under a manufacturing licence granted by Oxonica with authorization from Neuftec.

On 29 February 2008, IP Australia issued a re-examination report in respect of Neuftec’s Australian patent. The patent had been issued in 2006 with 10 claims. In the re-examination report, IP Australia confirmed the patentability of the 10 claims as originally granted in 2006 in re-examination proceedings initiated by Oxonica.

Contacts:
Ronen Hazarika
Neuftec Limited
Tel. +65-9633-8072

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024

Shedding light on perovskite hydrides using a new deposition technique: Researchers develop a methodology to grow single-crystal perovskite hydrides, enabling accurate hydride conductivity measurements May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Legal

180 Degree Capital Corp. Issues Open Letter to the Board and Shareholders of Enzo Biochem, Inc. February 4th, 2021

Nanogate: Meeting of creditors on November 4, 2020 September 4th, 2020

GLOBALFOUNDRIES Files Patent Infringement Lawsuits Against TSMC In the U.S. and Germany: Injunctions seek to prevent unlawful importation of infringing Taiwanese semiconductors August 26th, 2019

SUNY CNSE and Albany Law School Partner to Create First-of-its-Kind Nanotechnology Education and Training Program November 5th, 2013

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Finding quantum order in chaos May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project